Arbutus Biopharma Corp

NASDAQ:ABUSUnited States

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Contact Information

Headquarters

701 Veterans CircleWARMINSTER, PA, United States 18974

Phone

267-469-0914

Fax

604-419-3201

Executives

Independent Chairman of the Board

Frank Torti

Interim President, Chief Executive Officer, Director

Michael Mcelhaugh

Chief Financial Officer

David Hastings

Executive Vice President, General Counsel, Chief Compliance Officer and Secretary

Elizabeth Howard

Chief Scientific Officer

Michael Sofia